Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
Huy X NgoAva Y XuGustavo E VelásquezNan ZhangVincent K ChangEkaterina V KurbatovaWilliam C WhitworthErin SizemoreKia BryantWendy CarrMarc WeinerKelly E DooleyMelissa EngleSusan E DormanPayam NahidSusan SwindellsRichard E ChaissonPheona NsubugaMadeleine LourensRodney DawsonRadojka M SavicPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Flat-dosing of rifampicin at 600 mg daily may be a reasonable alternative to the incumbent weight-banded dosing strategy for the standard of care 6-month regimen. Future research should assess the optimal dosing strategy for rifampicin, at doses higher than the current recommendation.